Valuation : Seres Therapeutics, Inc.

Market Cap 4.98Cr 4.29Cr 4.06Cr 3.68Cr 6.91Cr 475.82Cr 6.94Cr 48Cr 19Cr 242.08Cr 19Cr 18Cr 764.94Cr P/E 2026 *
-1.43x
P/E 2027 * -1.01x
Enterprise Value 4.98Cr 4.29Cr 4.06Cr 3.68Cr 6.91Cr 475.82Cr 6.94Cr 48Cr 19Cr 242.08Cr 19Cr 18Cr 764.94Cr EV / Sales 2026 *
3.61x
EV / Sales 2027 * 182x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Seres Therapeutics, Inc.

1 day-1.76%
1 week-12.41%
Current month+2.04%
1 month+6.14%
3 months-12.11%
6 months-44.64%
Current year-66.33%
1 week 5
Extreme 5
5.75
1 month 4.32
Extreme 4.315
5.95
Current year 4.32
Extreme 4.315
16.42
1 year 4.32
Extreme 4.315
29.98
3 years 4.32
Extreme 4.315
60
5 years 4.32
Extreme 4.315
233.8
10 years 4.32
Extreme 4.315
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-1.76%-12.41%-68.51%-91.76% 4.98Cr
-2.11%-1.68%+43.40%+95.27% 6.69TCr
-0.23%-4.45%+32.50%+75.75% 6.2TCr
+1.67%+2.47%-11.32%+380.54% 2.83TCr
-1.05%-4.43%+28.84%+10.59% 2.46TCr
+0.34%-6.78%-0.01%-16.35% 2.43TCr
+0.43%-3.37%+16.22%-17.99% 1.94TCr
-3.03%-2.29%+181.72%+335.27% 1.68TCr
-1.94%-4.94%-8.15%+483.69% 1.42TCr
+3.24%-0.31%-7.34%+880.45% 1.4TCr
Average -0.44%-3.89%+20.73%+213.55% 2.7TCr
Weighted average by Cap. -0.56%-2.83%+31.24%+170.61%

Financials

2026 *2027 *
Net sales 1.38Cr 1.19Cr 1.13Cr 1.02Cr 1.91Cr 131.81Cr 1.92Cr 13Cr 5.14Cr 67Cr 5.18Cr 5.07Cr 211.9Cr 3L 2L 2L 2L 4L 2.61Cr 4L 26.5L 10.19L 1.33Cr 10.27L 10.05L 4.2Cr
Net income -3.75Cr -3.23Cr -3.06Cr -2.77Cr -5.2Cr -358.14Cr -5.23Cr -36Cr -14Cr -182.21Cr -14Cr -14Cr -575.76Cr -7.9Cr -6.8Cr -6.44Cr -5.84Cr -11Cr -754.29Cr -11Cr -77Cr -29Cr -383.75Cr -30Cr -29Cr -1.21TCr
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
11/26/11 $5.010 -1.76% 39,561
10/26/10 $5.100 -3.41% 32,070
09/26/09 $5.280 -5.04% 38,546
08/26/08 $5.560 -2.80% 36,652
04/26/04 $5.720 +1.42% 36,447
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.010USD
Average target price
17.00USD
Spread / Average Target
+239.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!